This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yoshikawa, T. Articles by Matsumoto, K. Search for Related Content PubMed PubMed Citation Articles by Yoshikawa, T. Articles by Matsumoto, K.

Effect of Adjuvant Endocrine and Adjuvant Chemoendocrine Therapies on Metastasis of Androgen-dependent Shionogi Carcinoma 115¹

Department of Pathology and Institute for Cancer Research, Osaka University Medical School, Kita-ku, Osaka 530 [T. Y., Y. K., K. M.], Shionogi Research Laboratory, Fukushima-ku, Osaka 533 [N. U.], and Kobe Women's Senior College, Chuo-ku, Kobe 650 [K. Y.], Japan

Shionogi carcinoma 115 is an androgen-dependent tumor, defined by its failure to grow in either female or castrated male DS mice, and by its ability to grow in intact male DS mice as well as in female or castrated male DS mice given androgen. Since spontaneous lung metastasis was found in about 50% of intact male DS mice on the 40th day after s.c. transplantation of the tumor, we investigated the effect of various therapies on development of metastasis. Therapies were started on the 25th day after transplantation. Castration alone did not reduce the frequency of metastasis, and tumor excision alone reduced the frequency slightly. However, castration following the tumor excision showed an excellent effect. Chemotherapy (cyclophosphamide, 80 mg/kg body weight, three times) with or without tumor excision also showed a beneficial effect, and the combination of the tumor excision, castration, and chemotherapy was the most effective among various therapies examined. These results indicate that the Shionogi carcinoma 115 tumor is a useful model for therapy against metastasis of human hormone-dependent cancers.

¹ Supported in part by grants from the Ministry of Education, Science and Culture, the Ministry of Health and Welfare, the Foundation for Cancer Research, and the Research Foundation for Cancer and Cardiovascular Diseases.

² To whom requests for reprints should be addressed, at Institute for Cancer Research, Osaka University Medical School, Nakanoshima 4-3-57, Kita-ku, 530 Japan.

Received 5/ 3/82. Accepted 6/15/83.